What baseline laboratory tests are recommended before initiating Eliquis (apixaban) therapy?

Baseline Laboratory Tests Before Initiating Eliquis (Apixaban)

Before starting Eliquis, you must obtain serum creatinine (to calculate creatinine clearance), complete blood count, liver function tests, and baseline coagulation parameters (PT/aPTT). These labs are essential for proper dosing and identifying contraindications 1, 2.

Essential Pre-Treatment Laboratory Assessment

Renal Function (Critical for Dosing)

• Serum creatinine to calculate creatinine clearance (CrCl) using the Cockcroft-Gault equation
• This determines whether dose adjustment is needed and identifies contraindications 1, 2
• For atrial fibrillation: If CrCl 15-50 mL/min AND patient has ≥2 of the following (age ≥80 years, weight ≤60 kg, serum creatinine ≥1.5 mg/dL), reduce dose to 2.5 mg twice daily 1, 2
• Apixaban is 27% renally excreted, making renal function assessment mandatory 2

Hepatic Function

• Liver function tests including AST, ALT, alkaline phosphatase, and bilirubin
• Apixaban is metabolized 25% via CYP3A4 and other hepatic pathways 2
• Contraindicated in Child-Pugh B (moderate) or C (severe) hepatic impairment 3
• Use with caution in Child-Pugh A (mild) hepatic impairment 3

Hematologic Parameters

• Complete blood count including hemoglobin and platelet count
• Establishes baseline to detect future bleeding complications
• Identifies pre-existing anemia or thrombocytopenia that may increase bleeding risk 2

Baseline Coagulation Studies

• PT/INR and aPTT for baseline reference
• While apixaban doesn't require routine monitoring, baseline values help interpret future coagulation tests if needed 4
• Note: Standard PT/aPTT are not sensitive enough to accurately measure apixaban's anticoagulant effect 4

Additional Considerations

Body Weight

• Document actual body weight, as weight ≤60 kg is a dose-reduction criterion for atrial fibrillation 1, 2

Age Documentation

• Age ≥80 years is a dose-reduction criterion for atrial fibrillation 1, 2

Common Pitfalls to Avoid

• Don't use PT/INR to monitor apixaban activity - these tests lack sensitivity and cannot accurately assess therapeutic effect 4
• Don't forget the "rule of 2" for atrial fibrillation dosing: reduce to 2.5 mg twice daily only if ≥2 criteria present (age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL) 1, 2
• Don't reduce dose for acute VTE treatment based on renal function alone - full dose (10 mg twice daily × 7 days, then 5 mg twice daily) is used regardless of renal function unless CrCl <15 mL/min 2
• Calculate CrCl using actual body weight, not ideal body weight, per the Cockcroft-Gault equation 3

If Specialized Testing Is Needed Later

• Anti-Xa chromogenic assays with apixaban-specific calibrators are the only accurate method to measure drug levels if clinically indicated (e.g., perioperative planning, suspected overdose, extremes of weight) 4, 5
• Standard anti-Xa assays calibrated for heparin are inappropriate 4